TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01277991
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)
Study: NCT01277991
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)
Study: NCT00531323
Drug: TMC125 once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (n =12): subjects will receive TMC125 400 mg once daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 400 mg once daily
Study: NCT00531323
Drug: TMC125 twice daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 2 (n = 12): TMC125 200 mg twice daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 200 mg twice daily
Study: NCT01695187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00723983
Drug: NP101 Study Patch
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NP101 study patch 4 hour application
Study: NCT01867437
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile solution (vehicle) for subcutaneous infusion
Study: NCT02781597
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 0.9% normal saline
Study: NCT00003499
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Low-grade non-Hodgkin's lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT02864498
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01208194
Drug: MGN1703
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution, 60 mg, twice a week, until progression
Study: NCT01208194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution, 60 mg, twice a week, until progression
Study: NCT00021255
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00021255
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01015287
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once orally
Study: NCT04467151
Drug: anti-SARS-CoV-2 plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of anti-SARS-CoV-2 convalescent plasma
Study: NCT01601405
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: On Days 0 and 14, each subject took a placebo capsule. Each capsule taken with water 150 mL.
Study: NCT00720538
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules
Study: NCT03296358
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 2 groups would receive IV Dexamethasone in ED and Oral prednisolone as home medication.
Study: NCT01942122
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control will be mefenamic acid 500 mg tablets, administered 3 times daily for 5 days during the menstrual period, i.e. day 1st to day 5th of the menstrual period. The drug will be given within the 8 weeks of study period (2 menstrual cycles).
Study: NCT01942122
Drug: DLBS1442 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study treatment will be DLBS1442 capsules at a dose of 3x200 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
Study: NCT02125435
Drug: ASP2408
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous
Study: NCT02125435
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous
Study: NCT02112916
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00345696
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2, orally, every 12 hours, continuous.
Study: NCT00348764
Drug: lauromacrogol
Normalized name: Lauromacrogol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03707587
Drug: M7824
Normalized name: M7824
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 1200 mg intravenous (IV) of M7824 on day 1 of a 14 day cycle, every other week, for up to 12 weeks total treatment (6 cycles).
Study: NCT02112916
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02112916
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02112916
Drug: Hydrocortisone Sodium Succinate
Normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IT
Study: NCT02112916
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO or IV
Study: NCT02112916
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Give PO
Study: NCT02112916
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT, IV, or PO
Study: NCT01537887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily for 10 days.
Study: NCT02105272
Drug: OPC-1085EL ophthalmic solution
Normalized name: Opcon-A Ophthalmic Product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00935571
Drug: propofol, remifentanil, sevoflurane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol: using target controlled infusion (TCI); 1-3ug/ml remifentanil: using TCI by 5-20 ng/ml sevoflurane: 2-3volume% (1-2 MAC)
Study: NCT02294591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on treatment of placebo
Study: NCT02590367
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX regimens are combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (different dose like FOLFOX4/FOLFOX6) via ambulatory pump administered for a period of 46 to 48 hours.~XELOX is a combination therapy of Oxaliplatin 130mg/ m\^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m\^2 bid, days 1-14, every 3 weeks.
Study: NCT02590367
Drug: HD6610 Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: the HD6610 Granule will be given 2 times a day.
Study: NCT02590367
Drug: HD6610 Granule placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the HD6610 Granule placebo will be given 2 times a day.
Study: NCT01989000
Drug: [F-18]HX4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 MBq \[F-18\]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.
Study: NCT03767322
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients will receive before and after coronary intervention
Study: NCT00133471
Drug: MF59 adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59 adjuvant is an oil-in-water emulsion.
Study: NCT03425747
Drug: Calcium Citrate
Normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subjects will be assigned to a calcium supplement (Carbonate or Citrate) at the same total amount of elemental calcium that they had taken before the study enrolment.
Study: NCT00074152
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given within 10 weeks after surgery.
Study: NCT01116583
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperatively (2 hours before surgery): 4 placebo capsules~Postoperative day 1: 1 placebo capsule x 2~Postoperative day 2: 1 placebo capsule x 3~Postoperative day 3: 1 placebo capsule x 4~Postoperative day 4: 1 placebo capsule x 4~Postoperative day 5: 1 placebo capsule x 4
Study: NCT02801383
Drug: Yallaferon®， the recombinant human interferon α-2b gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01604941
Drug: SPD602
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg/day orally twice daily for 24 weeks
Study: NCT01926236
Drug: 5 FU
Normalized name: i5 Functional Food Nutritional Powder for Suspension (Vanilla Delight)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 FU 400 mg/m2 (bolus), 2400 mg/m2 (infusion), q 14d, up to 12 cycles
Study: NCT02111564
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients, randomly allocated to the placebo arm, will receive one placebo tablet with or without food.
Study: NCT03930732
Drug: Inhaled Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation
Study: NCT03930732
Drug: Inhaled Long-Acting Beta Agonist
Normalized name: Sinex Long-Acting Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation
Study: NCT03930732
Drug: Inhaled Long-Acting Muscarinic Antagonist
Normalized name: Sinex Long-Acting Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation
Study: NCT03930732
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Study: NCT01356550
Drug: RO4917838
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose
Study: NCT02354703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + BBCET counseling
Study: NCT01968460
Drug: P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed Dose Combination of pramipexole 0.6 mg and rasagiline 0.75 mg once daily
Study: NCT01968460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01968460
Drug: P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed Dose Combination of pramipexole 0.3 mg and rasagiline 0.75 mg once daily
Study: NCT00397722
Drug: GW876008
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04363372
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules will be identical in appearance to active product.
Study: NCT02893358
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corresponding placebo once daily taken in the morning during 8:00-9:00. Duration: 12 months.
Study: NCT01548001
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2.5 mg/tablet, taken orally once a week, 4 tablets/week (week 1-week 4) , 6 tablets/week (week 5- week 52)
Study: NCT01693315
Drug: AMA0076
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01923545
Drug: PEG-G-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vial, 3.6mg/day or 6mg/day, single dosing per cycle, for 1 cycle
Study: NCT01410227
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syringe supplied with physiologic saline solution for infusion
Study: NCT01693315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02063139
Drug: Flutiform 50/5 ug (2 puffs bid) pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04471922
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose, 1 tablet QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
Study: NCT04322344
Drug: standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: antiviral drugs
Study: NCT00098917
Drug: autologous tumor cell vaccine
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00098917
Drug: therapeutic autologous dendritic cells
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04537663
Drug: Bacille Calmette-Guérin (BCG)
Normalized name: BACILLUS CALMETTE-GUERIN,TICE VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the intervention group will be vaccinated with the licensed BCG vaccine (Danish strain 1331, SSI, Denmark) using the standard vaccination technique for this vaccine (intradermal injection in the left upper arm).
Study: NCT02170662
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04133961
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion 0.3ml/kg/hour (normal saline in 20ml syringe)
Study: NCT04537663
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of sterile 0.9% NaCl.
Study: NCT02284035
Drug: EFV/TDF/FTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard combination therapy
Study: NCT02284035
Drug: ATV/r + TDF/FTC or DRV/r + TDF/FTC
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02599961
Drug: UX007
Normalized name: UX007
Approvals — FDA: no, EMA: no, PMDA: no
Description: UX007 is a liquid intended for oral (PO) administration.
Study: NCT05055193
Drug: Evaluation at 24 months corrected age: respiratory outcome, Neurodevelopmental outcome, Growth outcome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data concerning the 24 months corrected age outcomes were collected from the medical records of the ECL'AUR preterm infants follow-up network.
Study: NCT02284035
Drug: DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02284035
Drug: EFV plus ABC/3TC or RPV/TDF/FTC
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02284035
Drug: ATV/r plus ABC/3TC
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02284035
Drug: DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04592783
Drug: Antihypertensive Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medications will be initialed once BP is at predetermined threshold
Study: NCT02284035
Drug: RAL plus ABC/3TC
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01362205
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive placebo (normal saline)
Study: NCT02284035
Drug: Other ART regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03174483
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: nasal spray
Study: NCT02164422
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01100944
Drug: PXD101with cisplatin+doxorubicin+cyclophosphamide
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PXD101 will be given as a 48h continuous intravenous infusion (CIVI) starting on day 1, doxorubicin as a slow intravenous (IV) injection on days 2 and 3, cisplatin will be infused over 1 hour on day 2 and cyclophosphamide as a slow IV infusion on Day 3. Treatment will be given every 21 days for no more than 6 cycles or until disease progression. Treatment with PXD101 alone may continue until disease progression.
Study: NCT02853643
Drug: ASN002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose study with food effect
Study: NCT00139698
Drug: olmesartan alone or in combination with hydrochlorothiazide
Normalized name: hydrochlorothiazide / olmesartan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01172431
Drug: Indapamide
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide SR 1.5mg qd
Study: NCT03714490
Drug: CAPOX
Normalized name: Capecitabine and Oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive consolidation chemotherapy after 7-10 days of SCPRT completed, given in 3 week cycle of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once. In total, 4 cycles of neoadjuvant chemotherapy are scheduled before surgery.
Study: NCT01808651
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03423342
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo capsule
Study: NCT00279305
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous infusion
Study: NCT01405742
Drug: rF.VIII
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 IU/kg recombinant factor VIII will be given once-weekly or thrice-weekly by intravenous injection for 26 weeks. At 26 weeks after a 72 hour washout period, 40 IU/kg recombinant factor VIII will be given thrice-weekly or once-weekly, respectively, by intravenous injection until week 52, with up to two rescue doses per week for bleeds
Study: NCT01997879
Drug: AR-13324 Ophthalmic Solution, 0.02%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eyedrop
Study: NCT02517489
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.
Study: NCT01014832
Drug: Intensive insulin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive insulin therapy
Study: NCT00608985
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo matching almorexant tablets and 1 placebo matching over-encapsulated zolpidem
Study: NCT00718952
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.
Study: NCT02160574
Drug: 0.9% Physiological Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: The degree of skin irritation caused by 0.9% Physiological Saline will be graded and compared to ZuraPrep and ZuraPrep without IPA.
Study: NCT03491371
Drug: Methylsulfonic apatinib
Normalized name: 3,4-methylenedioxybenzoyl methylsulfone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-angiogenesis Tyrosine kinase inhibitor which specifically inhibits VEGFR-2.
Study: NCT04063930
Drug: LOKELMA 5 GM Powder for Oral Suspension
Normalized name: Lokelma 5 GM Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium zirconium cyclosilicate (a hyperkalemia treatment)
Study: NCT04063930
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT03200860
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo, 10 mg daily, oral, 30 days
Study: NCT03429946
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive spironolactone 12 hours and 3 hours before the initiation of the hyperinsulinemic clamp treatment.
Study: NCT03429946
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo 12 hours and 3 hours before the initiation of the hyperinsulinemic clamp treatment.
Study: NCT04342897
Drug: LY3127804
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT04342897
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT03440268
Drug: N Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrate NAC in the pre operatory and intra operatory moments and assess the influence in the outcomes
Study: NCT03440268
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: These participants will receive a saline solution in pre operatory with the same volume as the experimental group, and this solution will be administrated in 2 hours. During the surgery they will receive a new solution with the same volume of the experimental group, and this solution will be administrated in 6 hours too. The solutions will be covered by an opaque bag, so the participant will not see what is being administrated
Study: NCT00684515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets; once daily for 60 days
Study: NCT04225715
Drug: CpAM (RO7049389)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CpAM (RO7049389) will be administered orally
Study: NCT01934205
Drug: GSK2140944 (Single dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously as a single dose.
Study: NCT04123899
Drug: IGAD→GSTD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: IGAD First Period: Single oral administration of 1 tablet of Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug)~Other: Washout period 7 days~Drug: GSTD Second Period: Single oral administration of 1 tablet of Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)
Study: NCT00738595
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match EVT 302, 5 mg
Study: NCT01119417
Drug: Bq123
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose day: 100 nmol/min, single IV infusion for 15 min.